Table 2.

Risk of Myeloid, Lymphoid, and Solid Malignancies in Relatives of Patients With AML or MDS

Outcome in Relatives	AML(n = 20,579)	Controls(n = 90,406)	RR	95% CI	MDS(n = 3,994)	Controls(n = 15,818)	RR	95% CI
Myeloid
AML	15	70	0.9	0.5 to 1.9	3	11	1.1	0.30 to 3.8
MDS	4	10	1.8	0.6 to 5.7	2	2	4.0	0.4 to 43.1
AML/MDS	19	80	1.0	0.6 to 1.9	5	13	1.5	0.5 to 4.8
CML	9	29	1.3	0.6 to 2.9	1	2	2.0	0.2 to 21.6
Any myeloid malignancy*	28	109	1.1	0.7 to 1.8	6	15	1.6	0.6 to 4.5
PV	13	25	2.3	1.2 to 4.5	1	5	0.8	0.1 to 6.7
ET	5	22	1.0	0.4 to 2.6	0	3
MF	4	17	1.0	0.4 to 3.1	1	3	1.3	0.1 to 12.6
MPD NOS	3	12	1.1	0.3 to 3.9	2	0
Any myeloproliferative malignancy†	25	75	1.5	0.9 to 2.3	4	10	1.6	0.50 to 5.0
Any myeloid or myeloproliferative malignancy	53	182	1.3	0.9 to 1.8	10	24	1.6	0.7 to 3.6
Lymphoid
NHL	67	287	1.0	0.8 to 1.3	8	46	0.7	0.3 to 1.4
CLL	25	70	1.6	1.0 to 2.5	2	16	0.5	0.1 to 2.1
HL	20	64	1.3	0.8 to 2.2	2	10	0.8	0.2 to 3.6
MM	26	117	1.0	0.6 to 1.5	4	23	0.7	0.2 to 2.0
Any lymphoproliferative malignancy	140	539	1.1	0.9 to 1.4	16	95	0.7	0.4 to 1.1
ALL	7	26	1.2	0.5 to 2.7	1	2	2.0	0.2 to 21.3
Any hematologic malignancy	197	742	1.2	1.0 to 1.4	27	120	0.9	0.6 to 1.3
Any solid tumor	2,087	8,476	1.1	1.0 to 1.1	381	1,412	1.1	1.0 to 1.2

NOTE. Bolded entries indicate that risk ratio (RR) is significantly different from 1.0.

Abbreviations: ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; ET, essential thrombocythemia; HL, Hodgkin's lymphoma; MDS, myelodysplastic syndrome; MF, myelofibrosis; MM, multiple myeloma; MPD, myeloproliferative disorder; NHL, non-Hodgkin's lymphoma; NOS, not otherwise specified; PV, polycythemia vera.

^*Any myeloid malignancy includes AML, MDS, and CML.

^†Any myeloproliferative malignancy includes PV, ET, MF, and MPD NOS.

^‡Any lymphoproliferative malignancy includes NHL, HL, CLL, and MM.